[go: up one dir, main page]

WO2023002979A1 - Nouveau composé et agent prophylactique ou d'atténuation de la neuropathie périphérique le comprenant - Google Patents

Nouveau composé et agent prophylactique ou d'atténuation de la neuropathie périphérique le comprenant Download PDF

Info

Publication number
WO2023002979A1
WO2023002979A1 PCT/JP2022/028045 JP2022028045W WO2023002979A1 WO 2023002979 A1 WO2023002979 A1 WO 2023002979A1 JP 2022028045 W JP2022028045 W JP 2022028045W WO 2023002979 A1 WO2023002979 A1 WO 2023002979A1
Authority
WO
WIPO (PCT)
Prior art keywords
arabinitol
group
administration
peripheral neuropathy
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/028045
Other languages
English (en)
Japanese (ja)
Inventor
升三 西田
正寛 椿
朋也 武田
敏生 森川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kindai University
Original Assignee
Kindai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindai University filed Critical Kindai University
Priority to JP2023536756A priority Critical patent/JP7737164B2/ja
Publication of WO2023002979A1 publication Critical patent/WO2023002979A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom

Definitions

  • the present invention relates to a preventive or ameliorating agent for peripheral neuropathy, and more particularly to a preventive or ameliorating agent for peripheral neuropathy that can be suitably used for the prevention or amelioration of peripheral neuropathy caused by anticancer agents or diabetes. be.
  • peripheral neuropathy has a sensory hypersensitivity response (allodynia) that causes pain to stimuli that healthy people do not feel. Since the numbness and pain associated with this hyperesthesia response continues continuously for a long period of time, chemotherapy may be forced to be discontinued, which is regarded as a serious problem for chemotherapy.
  • anesthetics such as ketamine, antiepileptic drugs such as gabapentin, lamotrigine and clonazepam, antidepressants such as clomipramine and duloxetine, and Kampo medicines such as goshajinkigan and shakuyakukanzoto have been given vitamin B preparations.
  • anesthetics such as ketamine, antiepileptic drugs such as gabapentin, lamotrigine and clonazepam, antidepressants such as clomipramine and duloxetine
  • Kampo medicines such as goshajinkigan and shakuyakukanzoto have been given vitamin B preparations.
  • Patent Document 1 proposes a composition containing an amino acid containing serine and a lipid containing an n-3 fatty acid.
  • Patent Document 2 discloses that a specific cyclic amine compound can be a therapeutic or preventive agent for peripheral neuropathy.
  • peripheral neuropathy with similar symptoms develops as one of the symptoms of diabetes.
  • This peripheral neuropathy reduces the patient's quality of life. Therefore, there is a strong demand for an improvement in the symptoms of diabetic peripheral neuropathy.
  • Patent Document 3 discloses that a lactam compound is effective as a sugar transport enhancing agent, and prevents and treats diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic macroangiopathy, impaired glucose tolerance, or obesity. / Or it is described that it can be used as a therapeutic agent.
  • Patent Document 1 is composed of amino acids and fatty acids, it can be said that it has a relatively proven track record of safety for the human body. However, since it is a peptide, it is thought that further investigation is necessary regarding favorable pharmacokinetic properties. Although Patent Document 2 is a non-peptide, it is therefore necessary to verify the side effects of the drug itself.
  • Patent document 3 discloses that the lactam compound has the ability to transport sugar, including examples. Stay. The cause of diabetic peripheral neuropathy is still unclear. Diabetic peripheral neuropathy is a complication of diabetes, and it is important to stop the progression of diabetes first.
  • the present invention has been conceived in view of the above problems, and provides a preventive or ameliorating agent for peripheral neuropathy using ingredients other than peptides that have few side effects.
  • the preventive or ameliorating agent for peripheral neuropathy according to the present invention is effective both for chemotherapy-induced peripheral neuropathy and for diabetic peripheral neuropathy.
  • the preventive or ameliorating agent for peripheral neuropathy according to the present invention has the action of inhibiting the NK1 receptor.
  • the agent for preventing or improving peripheral neuropathy is a compound represented by the following formulas (1), (2), and (3), which is a derivative of D-(+)-arabinitol. characterized by containing at least one or more selected from
  • the present invention can provide a preventive or ameliorating agent for peripheral neuropathy. That is, they are three new substances obtained by adding specific functional groups to arabinitol. By administering or ingesting at least one selected from these three substances, numbness in the extremities, pain in the extremities, decreased deep tendon reflexes, decreased muscle strength, allodynia, and allodynia induced by cancer chemotherapy or diabetes. Hyperalgesia, finger dexterity dysfunction, gait disturbance, stumbling, falling, flexion disturbance (difficulty or inability to sit upright, cross-legged, sideways or chair sitting), paralysis of limbs, etc. are improved.
  • the preventive or ameliorating agent according to the present invention can also be used to prevent the above peripheral neuropathy by taking it at the same time as the start of chemotherapy or after being conscious of taking too much sugar.
  • providing a preventive or ameliorating agent for peripheral neuropathy that can be easily taken or taken at home is very useful for patients undergoing cancer treatment at home.
  • the patient's quality of life (QOL) is improved by preventing or improving peripheral neuropathy caused by cancer chemotherapy or diabetes.
  • arabinitol itself is a sugar alcohol and is known to be safe for the human body.
  • the added functional group is a fatty acid and does not have a serious effect on the human body. Therefore, it is highly expected that it is highly safe to the human body and has no major side effects.
  • Peripheral neuropathy is caused not only by cancer chemotherapy and diabetes, but also by administration of other drugs, trauma, infectious diseases, etc., but if the preventive or improving agent according to the present invention is used, these peripheral neuropathies can be prevented. It can also prevent or ameliorate symptoms.
  • FIG. 2 shows the results of a cold plate test when an arabinitol derivative was administered to mice together with oxaliplatin.
  • FIG. 3 shows the results of the von Frey test when an arabinitol derivative was administered to mice together with oxaliplatin.
  • FIG. 3 shows the results of a cold plate test when an arabinitol derivative was administered to mice together with paclitaxel.
  • FIG. 3 shows the results of the von Frey test when arabinitol derivatives were administered to mice together with paclitaxel.
  • FIG. 3 shows the results of a cold plate test when arabinitol derivatives were administered to mice together with vincristine.
  • FIG. 3 shows the results of the von Frey test when arabinitol derivatives were administered to mice together with vincristine.
  • FIG. 10 shows the results of a cold plate test when arabinitol derivatives were administered to mice together with bortezomib.
  • FIG. 3 shows the results of the von Frey test when arabinitol derivatives were administered to mice together with bortezomib.
  • FIG. 2 shows the results of a cold plate test in which an arabinitol derivative was administered to mice that developed peripheral neuropathy due to oxaliplatin.
  • FIG. 2 shows the results of the von Frey test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to oxaliplatin.
  • FIG. 3 shows the results of a cold plate test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to paclitaxel.
  • FIG. 10 shows the results of a cold plate test when arabinitol derivatives were administered to mice together with bortezomib.
  • FIG. 3 shows the results of the von Frey test when arabinitol derivatives were administered to
  • FIG. 2 shows the results of the von Frey test when an arabinitol derivative was administered to mice that developed peripheral neuropathy due to paclitaxel.
  • FIG. 10 shows the results of a cold plate test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to vincristine.
  • Fig. 10 shows the results of the von Frey test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to vincristine.
  • FIG. 2 shows the results of a cold plate test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to bortezomib.
  • FIG. 3 shows the results of the von Frey test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to bortezomib.
  • FIG. 10 shows the results of a cold plate test when arabinitol derivatives were administered to mice that developed peripheral neuropathy due to vincristine.
  • Fig. 10 shows the results of the von Frey test when arabin
  • FIG. 10 shows the results of a cold plate test when arabinitol derivatives were administered from the day streptozotocin was administered to mice.
  • FIG. 10 shows the results of the von Frey test when arabinitol derivatives were administered from the day streptozotocin was administered to mice.
  • Fig. 2 shows the results of a cold plate test in which an arabinitol derivative was administered to mice that developed diabetes and peripheral neuropathy due to administration of streptozotocin.
  • Fig. 10 shows the results of the von Frey test when an arabinitol derivative was administered to mice that developed diabetes and peripheral neuropathy due to administration of streptozotocin.
  • prevention means not only preventing the onset of peripheral neuropathy, but also includes the action of reducing the degree of symptoms at the time of onset, and “improving” means peripheral nerve It does not mean only radical treatment of disorders, but also includes the action of reducing or alleviating the degree of symptoms of peripheral neuropathy.
  • - indicates a range of "above, below”.
  • the preventive or ameliorating agent according to the present invention is a compound represented by Formula (1), Formula (2), and Formula (3) as an active ingredient.
  • the substance of formula (1) is a diester compound in which linoleoyl groups (ester bonds with linoleic acid) are bonded to both ends of D-(+)-arabinitol (CAS number 488-82-4). It is also called arabinitol-linoleic acid diester.
  • the substance of formula (2) is a diester compound in which ⁇ -linoleyl groups (ester bonds of linolenic acid) are bonded to both ends of D-(+)-arabinitol (CAS number 488-82-4). It is also called arabinitol-linolenic acid diester.
  • the substance of formula (3) is a diester compound in which eicosapentanoyl groups (ester bonds of eicosapentaenoic acid) are bonded to both ends of D-(+)-arabinitol (CAS number 488-82-4). It is also called arabinitol-eicosapentaenoic acid diester.
  • R is either formula (5), formula (6), or formula (7).
  • arabinitol derivatives or “various arabinitol derivatives”.
  • the synthesis methods for these will be described in detail later, but raw materials are arabinitol and respective fatty acids (linoleic acid, linolenic acid, eicosapentaenoic acid).
  • fatty acids linoleic acid, linolenic acid, eicosapentaenoic acid.
  • Each fatty acid is industrially produced and readily available.
  • D-(+)-arabinitol can be obtained by the conventional chemical reduction method of D-arabinol, or by the decomposition of microorganisms using glycerol as a carbon source.
  • the preventive or ameliorating agent according to the present invention can be provided in the form of pharmaceuticals, foods, and the like. Further, the improving agent according to the present invention can be provided with a label indicating that it is for improving peripheral neuropathy or preventing peripheral neuropathy.
  • the preventive or ameliorating agent according to the present invention when used as a pharmaceutical, it can be provided as a therapeutic agent for peripheral neuropathy (pharmaceutical composition) or a prophylactic agent for peripheral neuropathy (pharmaceutical composition).
  • the compounds of the invention can also be provided as NK1 receptor inhibitors.
  • the preventive or ameliorating agent according to the present invention when used as a pharmaceutical, it may be administered orally, transdermally, enterally, intravenously, transpulmonary, subcutaneously, transmucosally, intramuscularly, or the like. It may be appropriately set according to the degree of target peripheral neuropathy.
  • the arabinitol derivative may be prepared as it is or in combination with other additives into a desired dosage form.
  • specific examples of pharmaceuticals include internal preparations such as capsules, granules, powders, pills, tablets, jellies, and syrups; liquids, ointments, creams, lotions, gelling agents, patches , external preparations such as aerosols; injections and the like.
  • the preventive or ameliorating agent according to the present invention is to be made into a pharmaceutical
  • binders, lubricants, disintegrants, coloring agents, corrigents, preservatives, antioxidants, stabilizers Additives such as water, lower alcohols, solubilizers, surfactants, emulsion stabilizers, gelling agents, adhesives, fragrances, and pigments may be appropriately selected and formulated.
  • pharmacological ingredients such as vasodilating agents, adrenal corticosteroids, keratolytic agents, moisturizing agents, bactericidal agents, antioxidants, and cooling agents may also be contained, if necessary.
  • the content of the arabinitol derivative in the drug may be appropriately set according to the dosage form of the drug, etc. so that the daily dosage described later can be satisfied.
  • the total amount of arabinitol derivatives is (0.1 to 100)% by mass, preferably (15 to 80)% by mass, more preferably (30 to 70)% by mass
  • the total amount of arabinitol derivatives is (0.01 to 50)% by mass, preferably (0.1 to 40)% by mass, more preferably (0.5 to 30)% by mass. .
  • the preventive or ameliorating agent according to the present invention is made into a food
  • the food is provided as a food for preventing or improving peripheral neuropathy.
  • the arabinitol derivative may be prepared in a desired form as it is or in combination with other food materials or additives.
  • Foods include general processed foods such as luxury foods and health foods, foods with health claims such as foods with specified health uses, foods with nutrient claims, and foods with function claims, which are defined in the food with health claims system of the Ministry of Health, Labor and Welfare.
  • Specific foods include candy, gum, jelly, biscuits, cookies, rice crackers, bread, yogurt, ice cream, pudding, and other favorite foods; noodles; fish and livestock meat products; tea, soft drinks, coffee drinks, milk Beverages such as beverages, whey beverages and lactic acid beverages; general processed foods such as; capsules (soft capsules, hard capsules), tablets, granules, powders, and supplements such as jelly. Among these foods and drinks, supplements are preferred.
  • the content of the arabinitol derivative in the food may be appropriately set according to the type of food, etc., so as to satisfy the daily intake to be described later.
  • the total amount of arabinitol derivatives is (0.05 to 100)% by mass, preferably (10 to 80)% by mass, more preferably (20 to 60)% by mass.
  • the preventive or ameliorating agent according to the present invention is used for preventing or ameliorating peripheral neuropathy.
  • Applicable peripheral neuropathy symptoms include, for example, limb numbness, limb pain, decreased deep tendon reflex, decreased muscle strength, allodynia, hyperalgesia, dysgeusia, finger dexterity dysfunction, gait disorder, and stumbling. , falls, flexion disorders (difficulty or inability to sit upright, cross-legged, sitting sideways or sitting on a chair, etc.), paralysis of the limbs, etc.
  • the prophylactic or ameliorating agent according to the present invention is not particularly limited in terms of the inducer of peripheral neuropathy to which it is applied. Although it can be applied to any peripheral neuropathy caused by cancer chemotherapy or diabetes, it is particularly preferably applied to peripheral neuropathy induced by cancer chemotherapy or diabetes.
  • the type of anticancer agent is not particularly limited.
  • platinum agents include oxaliplatin, cisplatin, carboplatin, nedaplatin and the like.
  • alkylating agents include cyclophosphamide, ifosfamide, thiotepa, carbocone, nimustine hydrochloride and the like.
  • antimetabolites include 5-fluorouracil, methotrexate, doxifluridine, tegafur, cytarabine, gemcitabine and the like.
  • microtubule active agents include docetaxel, paclitaxel, vincristine, vinblastine, vindesine, vinorelbine, cabazitaxel, embulin and the like.
  • anticancer antibiotics include doxorubicin hydrochloride, mitomycin, amrubicin hydrochloride, pirarubicin hydrochloride, epirubicin hydrochloride, aclarubicin hydrochloride, mitoxantrone hydrochloride, bleomycin hydrochloride, and pepromycin sulfate.
  • topoisomerase inhibitors include irinotecan, nogitecan hydrochloride, and the like.
  • proteasome inhibitors include bortezomib, carfilzomib, ixazomib and the like.
  • histone deacetylase inhibitors include romidepsin and the like.
  • FLT3 tyrosine kinase inhibitors include gilteritinib and the like.
  • Antibody drugs specifically include pertuzumab, trastuzumab emtansine, brentuximab vedotin, polatuzumab vedotin, rituximab, obinutuzumab, blinatumomab, and bevacizumab.
  • ALK inhibitors include alectinib and brigtinib.
  • Specific examples of HER2/EGFR tyrosine kinase inhibitors include lapatinib and the like.
  • ALK/ROS1 tyrosine kinase inhibitors include crizotinib and lorlatinib.
  • TRK/ROS1 tyrosine kinase inhibitors include larotrectinib and entrectinib.
  • Specific examples of multikinase inhibitors include sorafenib, sunitinib, vandetanib, axitinib, regorafenib, cabozantinib and the like.
  • JAK inhibitors include ruxolitinib and the like.
  • BCR-ABL inhibitors include ponatinib and the like.
  • FGFR inhibitors include pemigatinib and the like.
  • MET inhibitors include tepotinib and the like.
  • BRAF inhibitors include vemurafenib and encorafenib.
  • MEK inhibitors include binimetinib and the like.
  • immunomodulators include thalidomide, lenalidomide, ponalidomide, and the like.
  • immune checkpoint inhibitors include nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab.
  • the preventive or ameliorating agent according to the present invention When the preventive or ameliorating agent according to the present invention is applied to peripheral neuropathy induced by the administration of an anticancer agent, the preventive or ameliorating agent according to the present invention is administered before or simultaneously with the start of administration of the anticancer agent. Administration or intake may be started, but administration or intake of the preventive or improving agent according to the present invention may be started during the period of administration of the anticancer agent or after the period of administration of the anticancer agent is completed.
  • the preventive or ameliorating agent according to the present invention When the preventive or ameliorating agent according to the present invention is applied to diabetic peripheral neuropathy, it can be ingested as an ameliorating agent after the onset of peripheral neuropathy. In addition, even before the onset of peripheral neuropathy, if the onset of diabetes can be confirmed, it can be used as a preventive agent by ingesting it.
  • the administration or intake amount of the preventive or improving agent according to the present invention can be appropriately selected according to symptoms, age, body weight, elapsed time after onset, combined therapeutic measures, and the like.
  • the total daily intake of arabinitol derivatives in mice effective for improving peripheral neuropathy when 6 mg/kg body weight of an anticancer agent was administered was 25 mg/kg body weight of mouse. 100 mg/mouse kg body weight or more is more preferable.
  • HED Human Equivalent Dose
  • the total daily intake of arabinitol derivatives should be 2.04 mg/human kg body weight or more, preferably 8.14 mg/human kg body weight or more. Therefore, the total daily intake of arabinitol derivatives for an adult male human is preferably 122.4 mg/day/adult or more, more preferably 489.2 mg/day/adult or more.
  • the preventive or ameliorating agent according to the present invention when orally administered or ingested, the total amount of administration or ingestion of the arabinitol derivative is 0.12 g / day / adult to 30 g / day / adult. .49 g/day/adult to 20 g/day/adult or less is preferred.
  • the preventive or ameliorating agent according to the present invention may be administered or taken in 1 or 2 to 3 divided doses per day so as to satisfy the daily dosage or intake.
  • At least one compound of the formulas (1) to (3) according to the present invention can be used to treat peripheral neuropathy caused by anticancer agents or diabetes.
  • the method for synthesizing the arabinitol derivative according to the present invention is described below.
  • D-(+)-arabinitol and the corresponding fatty acid are added to a dehydration condensing agent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, in an anhydrous pyridine solvent to form a fatty acid ester.
  • a certain arabinitol derivative is obtained.
  • the reaction mixture was poured into water and extracted with ethyl acetate.
  • the ethyl acetate layer obtained was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the desiccant was removed by filtration, and the resulting filtrate was evaporated under reduced pressure to obtain a composition.
  • the resulting composition was separated and purified by silica gel column chromatography (mobile phase: n-hexane:ethyl acetate 5:1, v/v) to obtain compound I-1 (880.0 mg, 26%).
  • the reaction mixture was poured into water and extracted with ethyl acetate.
  • the ethyl acetate layer obtained was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the desiccant was removed by filtration, and the resulting filtrate was evaporated under reduced pressure to obtain a composition.
  • the resulting composition was separated and purified by silica gel column chromatography (mobile phase: n-hexane:ethyl acetate 5:1, v/v) to obtain compound I-2 (1080.0 mg, 32%).
  • the reaction mixture was poured into water and extracted with ethyl acetate.
  • the ethyl acetate layer obtained was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the desiccant was removed by filtration, and the resulting filtrate was evaporated under reduced pressure to obtain a composition.
  • the resulting composition was separated and purified by silica gel column chromatography (mobile phase: n-hexane:ethyl acetate 5:1, v/v) to obtain compound I-3 (865.3 mg, 24%).
  • Example 2 Preventive Effect of Oxaliplatin on Peripheral Neuropathy Hyperesthesia such as allodynia (severe pain induced by tactile stimulation that does not normally cause pain) due to mechanical stimulation that occurs when the anticancer drug oxaliplatin is administered
  • Various arabinitol derivatives were orally administered to mice while administering oxaliplatin, and the following tests (Cold plate test and von Frey test) were performed.
  • oxaliplatin is an anticancer drug that corresponds to a platinum drug.
  • the dose (mg/kg) in all the examples below indicates the weight of the administered substance per 1 kg of body weight of the mouse.
  • These groups were respectively a control group, a 6 mg/kg oxaliplatin administration group, a 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linoleic acid diester administration group, a 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 6 mg/kg oxaliplatin administration group.
  • the horizontal axis is the elapsed time after administration (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg oxaliplatin administration group
  • the black square dashed line is the 6 mg / kg oxaliplatin + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the oxaliplatin-administered group (black circle dashed line) is considered to have developed a peripheral neuropathy (peripheral nerve hypersensitivity symptom) due to a shortened withdrawal response time after administration.
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • the arabinitol derivative-administered group the withdrawal reaction time after administration was the same as that of the control, despite the administration of oxaliplatin. From this, the arabinitol derivative-administered group suppressed peripheral neuropathy caused by the administration of oxaliplatin.
  • mice shown in (2-1) were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more. The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration
  • the vertical axis is the average avoidance response (score) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg oxaliplatin administration group
  • the black square dashed line is the 6 mg / kg oxaliplatin + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the oxaliplatin-administered group (broken black circle) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptoms) with an increase in the score (number of avoidance reactions) after administration.
  • the score after administration was almost the same as that of the control, although oxaliplatin was administered. From this, it can be said that the arabinitol derivative-administered group suppressed peripheral neuropathy caused by the administration of oxaliplatin.
  • Example 3 Preventive Effect of Paclitaxel on Peripheral Neuropathy Hyperesthesia such as allodynia (severe pain induced by tactile stimulation that does not normally cause pain) caused by mechanical stimulation that occurs when paclitaxel, an anticancer agent, is administered, and low temperature
  • the preventive effect of arabinitol derivatives against paresthesia in stimulation was investigated.
  • Various arabinitol derivatives were orally administered to mice while administering paclitaxel, and the following tests (Cold plate test and von Frey test) were performed.
  • Paclitaxel is an anticancer drug that corresponds to a microtubule active drug.
  • Paclitaxel 6 mg/kg was intraperitoneally administered to the paclitaxel-administered group and the paclitaxel + arabinitol derivative-administered group. This day was designated as day 0 of administration, and thereafter 6 mg/kg of paclitaxel was intraperitoneally administered to these mice on days 7 and 14.
  • These groups were respectively a control group, a 6 mg/kg paclitaxel administration group, a 6 mg/kg paclitaxel + 5 mg/kg arabinitol-linoleic acid diester administration group, a 6 mg/kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 6 mg/kg paclitaxel + 5 mg administration group. /kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the elapsed time after administration (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg paclitaxel administration group
  • the black square dashed line is the 6 mg / kg paclitaxel + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg / kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg paclitaxel + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the paclitaxel-administered group (black circle dashed line) is considered to have had a shortened withdrawal reaction time after administration and developed peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • the arabinitol derivative-administered group the withdrawal reaction time after administration was the same as that of the control, despite the administration of paclitaxel. From this, the arabinitol derivative-administered group suppressed peripheral neuropathy caused by administration of paclitaxel.
  • mice shown in (3-3) were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more. The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration
  • the vertical axis is the average avoidance response (score) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg paclitaxel administration group
  • the black square dashed line is the 6 mg / kg paclitaxel + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg / kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg paclitaxel + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*" (indicated as "*P ⁇ 0.01
  • the paclitaxel-administered group (black circle dashed line) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptom) with an increase in score (number of avoidance reactions) after administration.
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • score number of avoidance reactions
  • the arabinitol derivative-administered group the score after administration was almost the same as that of the control, although paclitaxel was administered. From this, it can be said that the arabinitol derivative-administered group suppressed the peripheral neuropathy caused by the administration of paclitaxel.
  • Example 4 Preventive Effect of Vincristine on Peripheral Neuropathy Hyperesthesia such as allodynia (severe pain induced by tactile stimuli that does not normally cause pain) and low temperature due to mechanical stimulation that occurs when the anticancer drug vincristine is administered
  • the preventive effect of arabinitol derivatives against paresthesia in stimulation was investigated.
  • Various arabinitol derivatives were orally administered to mice while administering vincristine, and the following tests (Cold plate test and von Frey test) were performed.
  • Vincristine is an anticancer drug that corresponds to a microtubule active drug.
  • mice Balb/c female mice aged 6 to 7 weeks were used. They were divided into 5 groups: a control group, a vincristine-administered group, and an arabinitol derivative-administered group (vincristine + 3 kinds of arabinitol derivatives-administered group). Each group consisted of 9 animals.
  • 0.2 mg/kg of vincristine was intraperitoneally administered to mice in the vincristine administration group and the vincristine + arabinitol derivative administration group. This day was designated as day 0 of administration, and 0.2 mg/kg vincristine was intraperitoneally administered to these mice on days 7 and 14 thereafter.
  • These groups were respectively a control group, a 0.2 mg/kg vincristine administration group, a 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linolenic acid diester administration group. , 0.2 mg/kg vincristine + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 0.2 mg/kg vincristine administration group
  • the black square dashed line is the 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is the black triangle dashed line.
  • the vincristine-administered group (black circle dashed line) is considered to have had a shortened withdrawal response time after administration and developed peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • the arabinitol derivative-administered group the withdrawal reaction time after administration was the same as that of the control, despite the administration of vincristine. From this, the arabinitol derivative-administered group suppressed peripheral neuropathy caused by administration of vincristine.
  • mice shown in (4-1) were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more. The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration
  • the vertical axis is the average avoidance response (score) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 0.2 mg/kg vincristine administration group
  • the black square dashed line is the 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is the black triangle dashed line.
  • the vincristine-administered group (black circle dashed line) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptoms) with an increase in score (number of avoidance reactions) after administration.
  • the score after administration was almost the same as that of the control, although vincristine was administered. From this, it can be said that the arabinitol derivative administration group suppressed the peripheral neuropathy that develops due to the administration of vincristine.
  • Example 5 Preventive effect of bortezomib on peripheral neuropathy Hyperesthesia and low temperature such as allodynia (severe pain induced by tactile stimulation that does not normally cause pain) due to mechanical stimulation that occurs when the anticancer agent bortezomib is administered
  • the preventive effect of arabinitol derivatives against paresthesia in stimulation was investigated.
  • Various arabinitol derivatives were orally administered to mice while administering bortezomib, and the following tests (Cold plate test and von Frey test) were performed.
  • Bortezomib is an anticancer drug that corresponds to a proteasome inhibitor.
  • mice (5-1) Administration of test substance Balb/c female mice aged 6 to 7 weeks were used. The animals were divided into 5 groups: a control group, a bortezomib-administered group, and an arabinitol derivative-administered group (bortezomib + 3 kinds of arabinitol derivatives-administered group). Each group consisted of 9 animals.
  • Bortezomib 1 mg/kg was intraperitoneally administered to the mice in the bortezomib-administered group and the bortezomib + arabinitol derivative-administered group. This day was designated as day 0 of administration, and 1 mg/kg of bortezomib was intraperitoneally administered to these mice on days 7 and 14 thereafter.
  • These groups were respectively a control group, a 1 mg/kg bortezomib administration group, a 1 mg/kg bortezomib + 5 mg/kg arabinitol-linoleic acid diester administration group, a 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 1 mg/kg bortezomib + 5 mg group. /kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the elapsed time after administration (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 1 mg / kg bortezomib administration group
  • the black square dashed line is the 1 mg / kg bortezomib + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 1 mg / 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the 1 mg/kg bortezomib + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the bortezomib-administered group (black circle dashed line) is considered to have had a shortened withdrawal reaction time after administration and developed peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • the arabinitol derivative-administered group the withdrawal reaction time after administration was the same as that of the control, despite the administration of bortezomib. From this, the arabinitol derivative administration group suppressed the peripheral neuropathy that develops due to the administration of bortezomib.
  • mice shown in (5-3) were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more. The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration
  • the vertical axis is the average avoidance response (score) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 1 mg / kg bortezomib administration group
  • the black square dashed line is the 1 mg / kg bortezomib + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 1 mg / 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the 1 mg/kg bortezomib + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*
  • the bortezomib-administered group (black circle dashed line) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptoms) with an increase in the score (number of avoidance reactions) after administration.
  • the score after administration was almost the same as that of the control, although bortezomib was administered. From this, it can be said that the arabinitol derivative administration group suppressed the peripheral neuropathy that develops due to the administration of bortezomib.
  • mice (6-1) Administration of test substance Balb/c female mice aged 6 to 7 weeks were used. The animals were divided into 5 groups: a control group, an oxaliplatin-administered group, and an arabinitol derivative-administered group (oxaliplatin + 3 types of arabinitol derivatives-administered group). Each group consisted of 9 animals.
  • mice other than the control group were intraperitoneally administered 6 mg/kg of oxaliplatin. This day was defined as the first day of administration (day 0), and the same dose of oxaliplatin was intraperitoneally administered to these mice three times on the 7th and 14th days.
  • arabinitol-eicosapentaenoic acid diester administration group 25 mg/kg of arabinitol derivative was orally administered daily.
  • These groups were respectively a control group, a 6 mg/kg oxaliplatin administration group, a 6 mg/kg oxaliplatin + 10 mg/kg arabinitol-linoleic acid diester administration group, a 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 6 mg/kg oxaliplatin administration group.
  • the horizontal axis is the elapsed time after administration (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg oxaliplatin administration group
  • the black square dashed line is the 6 mg / kg oxaliplatin + 10 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg oxaliplatin + 25 mg/kg arabinitol-eicosapentaenoic acid diester.
  • the withdrawal reaction time decreased uniformly by the 6th day after administration in the 4 groups administered with oxaliplatin other than the control group. It was considered that oxaliplatin caused peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • the horizontal axis is the elapsed time (days) after administration, which is the average avoidance response (score) of mice in each group. If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more.
  • the white circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg oxaliplatin administration group
  • the black square dashed line is the 6 mg / kg oxaliplatin + 10 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg/kg oxaliplatin + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg oxaliplatin + 25 mg/kg arabinitol-eicosapentaenoic acid diester.
  • peripheral neuropathy symptoms of peripheral nerve hypersensitivity
  • the arabinitol derivative also functions as a therapeutic composition (therapeutic agent) for peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • mice (6-1) Administration of test substance Balb/c female mice aged 6 to 7 weeks were used. The animals were divided into five groups: a control group, a paclitaxel-administered group, and an arabinitol derivative-administered group (paclitaxel + three types of arabinitol derivatives-administered group). Each group consisted of 9 animals.
  • mice other than the control group were intraperitoneally administered 6 mg/kg of paclitaxel. This day was defined as the first day of administration (day 0), and the same amount of paclitaxel was intraperitoneally administered to these mice three times on the 7th and 14th days.
  • paclitaxel + arabinitol derivative administration group 5 mg/kg of the arabinitol derivative was orally administered daily from day 6 after paclitaxel administration.
  • These groups were respectively a control group, a 6 mg/kg paclitaxel administration group, a 6 mg/kg paclitaxel + 5 mg/kg arabinitol-linoleic acid diester administration group, a 6 mg/kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 6 mg/kg paclitaxel + 5 mg administration group. /kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg paclitaxel administration group
  • the black square dashed line is the 6 mg / kg paclitaxel + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg / kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg paclitaxel + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the withdrawal reaction time decreased uniformly by the 6th day after administration in the four groups administered with paclitaxel other than the control group.
  • Peripheral neuropathy peripheral nerve hypersensitivity symptoms was thought to have developed due to paclitaxel.
  • mice shown in (1) of this example were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration, which is the average avoidance response (score) of mice in each group. If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more.
  • the open circle solid line is the control group
  • the black circle dashed line is the 6 mg / kg paclitaxel administration group
  • the black square dashed line is the 6 mg / kg paclitaxel + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 6 mg / kg paclitaxel + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the administration group of 6 mg/kg paclitaxel + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the paclitaxel-administered group (black circle dashed line) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptom) with an increase in score (number of avoidance reactions) after administration.
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • score number of avoidance reactions
  • paclitaxel administration improved peripheral neuropathy (peripheral nerve hypersensitivity symptoms) by taking arabinitol derivatives. Therefore, it was found that the arabinitol derivative also functions as a therapeutic composition (therapeutic agent) for peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • mice Female mice aged 6 to 7 weeks were used. They were divided into 5 groups: a control group, a vincristine-administered group, and an arabinitol derivative-administered group (vincristine + 3 kinds of arabinitol derivatives-administered group). Each group consisted of 9 animals.
  • mice other than the control group were intraperitoneally administered 0.2 mg/kg of vincristine. This day was defined as the first day of administration (day 0), and the same amount of vincristine was intraperitoneally administered to these mice three times on the 7th and 14th days.
  • These groups were respectively a control group, a 0.2 mg/kg vincristine administration group, a 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linolenic acid diester administration group. , 0.2 mg/kg vincristine + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the 0.2 mg/kg vincristine administration group
  • the black square dashed line is the 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is the black triangle dashed line.
  • the withdrawal reaction time uniformly decreased by 6 days after administration in the four groups other than the control group that had been administered vincristine.
  • Peripheral neuropathy peripheral hypersensitivity symptom was considered to have developed due to vincristine.
  • mice shown in (1) of this example were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration, which is the average avoidance response (score) of mice in each group. If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more.
  • the white circle solid line is the control group
  • the black circle dashed line is the 0.2 mg/kg vincristine administration group
  • the black square dashed line is the 0.2 mg/kg vincristine + 5 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is the black triangle dashed line.
  • the vincristine-administered group (black circle dashed line) is considered to have developed peripheral neuropathy (peripheral nerve hypersensitivity symptoms) with an increase in score (number of avoidance reactions) after administration.
  • the score after administration decreased despite the administration of vincristine, and after 21 days, it became almost the same as the control. From this, it can be said that the arabinitol derivative administration group suppressed the peripheral neuropathy that develops due to the administration of vincristine.
  • peripheral neuropathy symptoms of peripheral nerve hypersensitivity
  • the arabinitol derivative also functions as a therapeutic composition (therapeutic agent) for peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • Bortezomib 1 mg/kg was intraperitoneally administered to mice other than the control group. This day was defined as the first day of administration (day 0), and the same dose of bortezomib was intraperitoneally administered to these mice three times on days 7 and 14.
  • bortezomib + arabinitol derivative administration group 5 mg/kg of the arabinitol derivative was orally administered daily from day 6 after administration of bortezomib.
  • These groups were respectively a control group, a 1 mg/kg bortezomib administration group, a 1 mg/kg bortezomib + 5 mg/kg arabinitol-linoleic acid diester administration group, a 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group, and a 1 mg/kg bortezomib + 5 mg group. /kg arabinitol-eicosapentaenoic acid diester administration group.
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the open circle solid line is the control group
  • the black circle dashed line is the 1 mg / kg bortezomib administration group
  • the black square dashed line is the 1 mg / kg bortezomib + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 1 mg / 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the 1 mg/kg bortezomib + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the withdrawal reaction time uniformly decreased by 6 days after administration in the four groups administered with bortezomib other than the control group.
  • Bortezomib was considered to have caused peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • Three of the administration groups tended to have longer latencies from day 6 onwards, and on day 12, these three groups and the control group showed significant withdrawal response times ( latency) increased.
  • mice shown in (1) of this example were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration, which is the average avoidance response (score) of mice in each group. If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more.
  • the open circle solid line is the control group
  • the black circle dashed line is the 1 mg / kg bortezomib administration group
  • the black square dashed line is the 1 mg / kg bortezomib + 5 mg / kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is 1 mg / 1 mg/kg bortezomib + 5 mg/kg arabinitol-linolenic acid diester administration group
  • the dotted black diamond line is the 1 mg/kg bortezomib + 5 mg/kg arabinitol-eicosapentaenoic acid diester administration group.
  • the score (number of avoidance reactions) increased after administration, and it is considered that peripheral neuropathy (peripheral nerve hypersensitivity symptom) developed.
  • the score after administration decreased despite the administration of bortezomib, and after 21 days, it became almost the same as the control. From this, it can be said that the arabinitol derivative administration group suppressed the peripheral neuropathy that develops due to the administration of bortezomib.
  • mice (10-1) Administration of test substance 6- to 7-week-old C57BL/6J male mice were used. They were divided into 5 groups: a control group, a streptozotocin-administered group, and an arabinitol derivative-administered group (streptozotocin + 3 kinds of arabinitol derivative-administered groups). Each group consisted of 9 animals.
  • streptozotocin 200 mg/kg of streptozotocin was intraperitoneally administered to the mice of the streptozotocin-administered group and the streptozotocin + arabinitol derivative-administered group.
  • a high dose of streptozotocin destroys pancreatic cells in mice. As a result, insulin secretion is lost, and mice can develop diabetes.
  • This day was defined as the first day of administration (day 0).
  • the streptozotocin was administered only on the first day of administration.
  • These groups are respectively referred to as a control group, a streptozotocin administration group, a streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group, a streptozotocin + 1 mg/kg arabinitol-linolenic acid diester administration group, and a streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester administration group. .
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the streptozotocin administration group
  • the black square dashed line is the streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is streptozotocin + 1 mg/kg arabinitol-linolenic acid.
  • the diester-administered group, and the dotted black diamond line is the streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester-administered group. Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*" (indicated as "*P ⁇ 0.01 vs control group" in the figure).
  • the streptozotocin-administered group (broken black circle) is considered to have had a shortened withdrawal response time after the administration and developed peripheral neuropathy (peripheral nerve hypersensitivity symptom).
  • peripheral neuropathy peripheral nerve hypersensitivity symptom
  • the arabinitol derivative-administered group the withdrawal reaction time after administration was the same as that of the control, despite the administration of streptozotocin. From this, the arabinitol derivative administration group suppressed diabetes-induced peripheral neuropathy developed by administration of streptozotocin.
  • mice shown in (10-3) were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more. The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration
  • the vertical axis is the average avoidance response (score) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the streptozotocin administration group
  • the black square dashed line is the streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is streptozotocin + 1 mg/kg arabinitol-linolenic acid.
  • the diester-administered group, and the dotted black diamond line is the streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester-administered group. Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*" (indicated as "*P ⁇ 0.01 vs control group" in the figure).
  • streptozotocin 200 mg/kg of streptozotocin was intraperitoneally administered to the mice of the streptozotocin-administered group and the streptozotocin + arabinitol derivative-administered group.
  • a high dose of streptozotocin destroys pancreatic cells in mice. As a result, insulin secretion is lost, and mice can develop diabetes.
  • This day was defined as the first day of administration (day 0).
  • the streptozotocin was administered only on the first day of administration.
  • These groups are respectively referred to as a control group, a streptozotocin administration group, a streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group, a streptozotocin + 1 mg/kg arabinitol-linolenic acid diester administration group, and a streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester administration group. .
  • Example 11-1 Cold plate test The five groups of mice shown in this example (Example 11-1) were tested for the effect of arabinitol derivatives on hypoesthesia due to cold stimulation. Each group of mice was placed on a cold plate set at 4° C., and reaction time (latency) until escape was measured. It is considered that the shorter the latency, the more avoidance of cold stimulation by the cold plate. The results are shown in FIG.
  • the horizontal axis is the post-administration elapsed time (days), and the vertical axis is the average escape reaction time (seconds) of mice in each group.
  • the white circle solid line is the control group
  • the black circle dashed line is the streptozotocin administration group
  • the black square dashed line is the streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is streptozotocin + 1 mg/kg arabinitol-linolenic acid.
  • the diester-administered group, and the dotted black diamond line is the streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester-administered group. Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*" (indicated as "*P ⁇ 0.01 vs control group" in the figure).
  • the withdrawal reaction time (latency) uniformly decreased by 21 days after administration. It was considered that streptozotocin caused diabetic peripheral neuropathy (peripheral nerve hypersensitivity symptoms).
  • mice shown in this example were placed in cages, and filaments with a strength of 0.16 g were pressed against the soles of their hind limbs to measure the number of avoidance reactions (scores). The results are shown in FIG.
  • the horizontal axis is the elapsed time (days) after administration, which is the average avoidance response (score) of mice in each group. If the avoidance frequency is large, it is considered that the stimulation by the filament is avoided more.
  • the white circle solid line is the control group
  • the black circle dashed line is the streptozotocin administration group
  • the black square dashed line is the streptozotocin + 1 mg/kg arabinitol-linoleic acid diester administration group
  • the black triangle dashed line is streptozotocin + 1 mg/kg arabinitol-linolenic acid.
  • the diester-administered group, and the dotted black diamond line is the streptozotocin + 1 mg/kg arabinitol-eicosapentaenoic acid diester-administered group. Those that can be judged to have significant differences from the control group by a test with a significance level of 1% are marked with "*" (indicated as "*P ⁇ 0.01 vs control group" in the figure).
  • NK1 Receptor Binding Inhibitory Effect U251 cells (human glioblastoma cell line) were cultured in RPMI1640 medium for 2 days. Then, 1 ⁇ M arabinitol-linoleic acid diester, 1 ⁇ M arabinitol-linolenic acid diester, 10 ⁇ M arabinitol-eicosapentaenoic acid diester were added, stained with substance P-FAM after 1 hour, and stained with substance P-FAM using BD LSRFortessa. The amount of binding was measured.
  • the horizontal axis represents the binding amount of substance P-FAM
  • the vertical axis represents the number of cells (indicated as "Count").
  • the solid line in the panel indicates the control containing neither Substance P-FAM nor the compound
  • the dashed line indicates the addition of 1 ⁇ M Substance P-FAM
  • the dotted line indicates the addition of 1 ⁇ M Substance P-FAM and each compound.
  • the amount of binding of substance P-FAM was remarkably increased in the substance P-FAM addition group compared to the control group to which the compound and substance P-FAM were not added.
  • the preventive or ameliorating agent according to the present invention can be used as a selective NK1 receptor inhibitor to ameliorate or prevent peripheral neuropathy. It can also be used to treat peripheral neuropathy. In particular, it should be suitably used for reducing, mitigating or preventing peripheral neuropathy caused by administration of DNA replication inhibitors (platinum agents (oxaliplatin, etc.) and alkylating agents) and peripheral neuropathy concomitant with diabetes. can be done.
  • DNA replication inhibitors platinum agents (oxaliplatin, etc.) and alkylating agents
  • peripheral neuropathy concomitant with diabetes can be done.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Jusqu'à présent, aucun médicament ou aliment médical n'est capable de prévenir ou d'atténuer particulièrement une neuropathie périphérique induite par un agent anticancéreux tel que l'oxaliplatine parmi des effets secondaires indésirables induits par un médicament.　L'invention concerne un agent prophylactique ou d'atténuation pour une neuropathie périphérique, qui comprend au moins un composé choisi parmi les composés représentés par les formules (1) à (3) en tant que principe actif. L'agent prophylactique ou d'atténuation peut soulager l'engourdissement des membres, la douleur dans les membres, la diminution du réflexe des tendons profonds, la perte de la force musculaire, l'allodynie, l'hyperalgésie, un dysfonctionnement dans la capacité motrice des doigts, une perturbation de la marche, le trébuchement, la chute, les difficultés de flexion corporelle (difficultés ou incapacités associées à des postures telles que s'asseoir sur les talons, s'asseoir avec les jambes croisées, s'asseoir avec les jambes pliées latéralement, ou s'asseoir sur une chaise), la paralysie des membres ou analogues qui sont induits par des médicaments tels que des agents anticancéreux ou induits par le diabète.　[Formule 200] [Formule 201] [Formule 202]
PCT/JP2022/028045 2021-07-20 2022-07-19 Nouveau composé et agent prophylactique ou d'atténuation de la neuropathie périphérique le comprenant Ceased WO2023002979A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023536756A JP7737164B2 (ja) 2021-07-20 2022-07-19 新規化合物およびそれを用いた末梢神経障害の予防又は改善剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-120002 2021-07-20
JP2021120002 2021-07-20

Publications (1)

Publication Number Publication Date
WO2023002979A1 true WO2023002979A1 (fr) 2023-01-26

Family

ID=84980019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/028045 Ceased WO2023002979A1 (fr) 2021-07-20 2022-07-19 Nouveau composé et agent prophylactique ou d'atténuation de la neuropathie périphérique le comprenant

Country Status (2)

Country Link
JP (1) JP7737164B2 (fr)
WO (1) WO2023002979A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004244393A (ja) * 2003-02-17 2004-09-02 Tetsuo Yoshioka 細胞機能調節剤
JP2009263270A (ja) * 2008-03-31 2009-11-12 Lion Corp Ｎｋ１受容体アンタゴニスト組成物
WO2015163316A1 (fr) * 2014-04-22 2015-10-29 味の素株式会社 Composition pour prévenir ou améliorer la neuropathie périphérique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004244393A (ja) * 2003-02-17 2004-09-02 Tetsuo Yoshioka 細胞機能調節剤
JP2009263270A (ja) * 2008-03-31 2009-11-12 Lion Corp Ｎｋ１受容体アンタゴニスト組成物
WO2015163316A1 (fr) * 2014-04-22 2015-10-29 味の素株式会社 Composition pour prévenir ou améliorer la neuropathie périphérique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JO YOUN YI, LEE JI YEON, PARK CHUL-KYU: "Resolvin E1 Inhibits Substance P-Induced Potentiation of TRPV1 in Primary Sensory Neurons", MEDIATORS OF INFLAMMATION., RAPID COMMUNICATION OF OXFORD LTD., OXFORD., GB, vol. 2016, 1 January 2016 (2016-01-01), GB , pages 1 - 9, XP093026696, ISSN: 0962-9351, DOI: 10.1155/2016/5259321 *
MIYAZAWA MITSUO; TAKAHASHI TOSHIYUKI; HORIBE ISAO; ISHIKAWA RYUUZOU: "Two new aromatic compounds and a new d-arabinitol ester from the mushroom Hericium erinaceum", TETRAHEDRON, ELSEVIER SIENCE PUBLISHERS, AMSTERDAM, NL, vol. 68, no. 7, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 2007 - 2010, XP028889097, ISSN: 0040-4020, DOI: 10.1016/j.tet.2011.11.068 *
PIAO JUNKUI, ADACHI SHUJI: "Enzymatic preparation of fatty acid esters of sugar alcohols by condensation in acetone using a packed-bed reactor with immobilized Candida antarctica lipase", BIOCATALYSIS AND BIOTRANSFORMATION., TAYLOR & FRANCIS, GB, vol. 22, no. 4, 1 July 2004 (2004-07-01), GB , pages 269 - 274, XP093026694, ISSN: 1024-2422, DOI: 10.1080/10242420400005788 *
PIAO JUNKUI, KOBAYASHI TAKASHI, ADACHI SHUJI, NAKANISHI KAZUHIRO, MATSUNO RYUICHI: "Continuous synthesis of lauroyl or oleoyl erythritol by a packed-bed reactor with an immobilized lipase", PROCESS BIOCHEMISTRY, ELSEVIER LTD, GB, vol. 39, no. 6, 1 February 2004 (2004-02-01), GB , pages 681 - 686, XP093026695, ISSN: 1359-5113, DOI: 10.1016/S0032-9592(03)00151-1 *

Also Published As

Publication number Publication date
JPWO2023002979A1 (fr) 2023-01-26
JP7737164B2 (ja) 2025-09-10

Similar Documents

Publication Publication Date Title
JP2024133114A (ja) 神経刺激性ステロイドおよびそれらの使用方法
US10617660B2 (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN1708234A (zh) 抗氧化组合物
US7846913B2 (en) Compositions and methods to treat recurrent medical conditions
WO2014003154A1 (fr) Agent pour prévenir la détérioration de la fonction endothéliale vasculaire ou améliorer la fonction endothéliale vasculaire
US20220273600A1 (en) Lithium salts of n-substituted glycine compounds and uses thereof
JP2003252765A (ja) 腸管運動機能不全性疾患の治療剤
JP2019182881A (ja) 末梢神経障害の予防又は改善用組成物
JPWO2002055091A1 (ja) 抗アレルギー剤
US11793845B2 (en) Composition for ameliorating peripheral sensory neuropathy
JP5116071B2 (ja) Ｄ−アロースおよびｄ−プシコースの抗神経因性疼痛効果の利用
JP7737164B2 (ja) 新規化合物およびそれを用いた末梢神経障害の予防又は改善剤
WO2019146735A1 (fr) Composition pour prévention ou amélioration de la douleur nociceptive
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
US20100151066A1 (en) Composition for suppressing appetite, improving tone and mood, with a natural antidepressant activity and with an antiasthenic effect
WO2022168968A1 (fr) Agent pour prévenir ou soulager la neuropathie périphérique
CN119139297A (zh) 包含利美尼定的组合物的应用
JP6800404B2 (ja) 自律神経調節剤
AU2020391291B2 (en) Combination therapy of cycloserine and lithium for the treatment of depression
TW201242980A (en) Compositions and methods for improving brain function
JP2024017059A (ja) 感冒症状抑制剤
KR20250151408A (ko) 화학 요법 유발 말초 신경 장애의 치료 또는 예방을 위한 의약
JP2004175786A (ja) Ｉ型アレルギー疾患治療用組成物
CN111166868A (zh) 一种用于治疗神经疾病和障碍的组合物
WO2001052828A2 (fr) Prevention, au moyen de glutamine, de la diarrhee tardive induite par l'irinotecan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22845912

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023536756

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22845912

Country of ref document: EP

Kind code of ref document: A1